FDA targets companies marketing unapproved weight‑loss drugs online
The FDA's latest round of warning letters points to an intensifying regulatory trend targeting companies marketing and selling GLP-1 and related compounds online.
The US Food and Drug Administration (FDA) has issued a new raft of warning letters to firms marketing glucagon‑like peptide‑1 (GLP‑1) receptor agonists and related compounds without required regulatory authorization.
On April 7, 2026, the FDA cited seven companies for distributing GLP‑1 products, dual GLP‑1/glucose‑dependent insulinotropic polypeptide (GIP) products, and
